Hong Zhang, PhDFox Chase Cancer Center Regulated exocytosis and gamma synuclein in ovarian cancer: a biomarker of disease γ synuclein (gamma synuclein) is a protein that may shuttle other proteins which promote the growth and spread of cancer. This study will identify these protein promoters and assess whether γ synuclein could be used in screening.
Read More
Lainie Martin, MDFox Chase Cancer Center A pilot study to evaluate the role of STAT3 in angiogenesis, tumor cell proliferation and survival in ovarian cancer This study will look at a family of genes (STAT3) and their impact on the process of cell death. With a greater understanding the role of STAT3, researchers hope to […]
Read More
Dusica Cvetkovic, MDFox Chase Cancer Center Validation of an ovarian cancer biomarker panel in high-risk women This study will examine ovaries removed during prophylactic (preventative) surgery, before ovarian cancer is discovered or suspected. The hypothesis is that aberrant DNA methylation can be detected in the blood of women prior to the onset of clinical symptoms. […]
Read More
Thuy-Vy Do, PhDFox Chase Cancer Center Preclinical Evaluation of Aurora A Kinase and PARP Inhibitor Combination Therapy Women carrying mutations in the breast-cancer associated 1 or 2 (BRCA1/2) genes are at higher risk for developing epithelial ovarian cancer. BRCA1/2 play critical roles in repairing DNA and helping genes avoid mutation. Interestingly, BRCA1/2 is not functioning […]
Read More
Denise Connolly, PhDFox Chase Cancer Center2015 Pape Family Pilot Award Sensitizing ovarian cancer to PARP inhibition PARP inhibitors are among the most promising class of targeted therapeutics for the treatment of ovarian cancer. Patients with mutations in BRCA genes and some patients with sporadic cancers are particularly sensitive to this class of drugs, presumably because […]
Read More
Neil Johnson, PhDFox Chase Cancer Center Investigating the ability of splicing inhibitors to target BRCA1 mutant ovarian cancer Though patients with mutations in the BRCA1 gene respond better to cisplatin and PARP inhibitors than patients without mutations, resistance to these drugs remains a major obstacle for the successful long-term treatment of ovarian cancer. Dr. Johnson’s […]
Read More